Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (9939)	1/6/2004 1:09:28 PM
From: Biomaven	Read Replies (2) \| Respond to of 52153

This from the WSJ yesterday on Indian stocks: Fund managers picked pharmaceuticals and cement stocks as the best choices in India for this year. Indian pharmaceutical companies have benefited from a rise in outsourcing orders with global giants using India's low-cost facilities to make drugs. This has sharply boosted the earnings of Indian drug companies. Divi's Laboratories Ltd., for instance, saw its net profit rise 50% for the year ended March 2003 and it is expected to maintain its growth. This factor, combined with the relatively low valuations of Indian pharmaceutical companies, could make them an attractive buy. Most of the midcap Indian drug companies are trading at less than 10 times their forecast fiscal 2005 earnings, compared with 16 times for the benchmark Sensitive Index of the Bombay Stock Exchange. online.wsj.com